Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qingnao Jiangya Pian (清脑降压片) is a traditional Chinese medicine (TCM) oral tablet developed and manufactured by Jilin Fukang Pharmaceutical for the treatment of hypertension. Formulated according to traditional principles, it is designed to clear liver fire, calm liver yang, and reduce blood pressure. The medication is primarily indicated for patients presenting with essential hypertension and associated symptoms such as dizziness, headache, and insomnia, which are attributed to hyperactivity of liver-yang in TCM theory. As a multi-herb formulation, its therapeutic effects are derived from the synergistic actions of its constituents, which typically include Scutellariae Radix (Huangqin), Phellodendri Chinensis Cortex (Huangbai), and Rhei Radix et Rhizoma (Dahuang), known for their anti-inflammatory, sedative, and potential vasodilatory properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qingnao jiangya pian.